2023 Dermatomyositis Pipeline Landscape Report Unveils Promising Growth Potential with 10+ Companies and Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dermatomyositis - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

The report offers comprehensive insights into the Dermatomyositis pipeline landscape, covering 10+ companies and 10+ pipeline drugs. It provides detailed drug profiles, clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as highlighting inactive pipeline products.

Key Highlights:

• Dermatomyositis is a rare acquired immune-mediated muscle disease characterized by muscle weakness and skin rash. It falls under the category of idiopathic inflammatory myopathies (IIM) and presents with characteristic skin findings and symmetric proximal skeletal muscle weakness.

• The report includes detailed descriptions of pipeline drugs, such as Lenabasum by Corbus Pharmaceuticals and KZR-616 by Kezar Life Sciences, offering novel approaches to treat and improve Dermatomyositis.

Companies Mentioned:

• Corbus Pharmaceuticals
• Kezar Life Sciences
• Pfizer
• CSL Behring
• Viela Bio
• PAEAN Biotechnology
• Alexion Pharmaceuticals

Key Topics Covered:

1. Introduction
2. Executive Summary
3. Dermatomyositis: Overview
   • Causes
   • Mechanism of Action
   • Signs and Symptoms
   • Diagnosis
   • Disease Management
4. Pipeline Therapeutics
   • Comparative Analysis
   • Therapeutic Assessment
   • Assessment by Product Type
   • Assessment by Stage and Product Type
   • Assessment by Route of Administration
   • Assessment by Stage and Route of Administration
   • Assessment by Molecule Type
   • Assessment by Stage and Molecule Type
5. Dermatomyositis - Analytical Perspective
6. Late Stage Products (Phase III)
   • Comparative Analysis
   • Lenabasum: Corbus Pharmaceuticals
     • Product Description
     • Research and Development
     • Product Development Activities
7. Mid Stage Products (Phase II)
   • Comparative Analysis
   • KZR-616: Kezar Life Sciences
     • Product Description
     • Research and Development
     • Product Development Activities
8. Early Stage Products (Phase I/II)
   • Comparative Analysis
   • PN-101: Paean Biotechnology
     • Product Description
     • Research and Development
     • Product Development Activities
9. Inactive Products
   • Comparative Analysis
10. Dermatomyositis Key Companies
11. Dermatomyositis Key Products
12. Dermatomyositis - Unmet Needs
13. Dermatomyositis - Market Drivers and Barriers
14. Dermatomyositis - Future Perspectives and Conclusion
15. Dermatomyositis - Analyst Views
16. Dermatomyositis Key Companies
17. Appendix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/iml83d

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.